A detailed history of Legal & General Group PLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Legal & General Group PLC holds 281,412 shares of BCRX stock, worth $2.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
281,412
Previous 276,691 1.71%
Holding current value
$2.14 Million
Previous $1.41 Million 23.77%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $19,497 - $32,055
4,721 Added 1.71%
281,412 $1.74 Million
Q1 2024

May 14, 2024

SELL
$4.89 - $7.65 $158,250 - $247,569
-32,362 Reduced 10.47%
276,691 $1.41 Million
Q4 2023

Feb 15, 2024

SELL
$4.98 - $6.77 $382,110 - $519,455
-76,729 Reduced 19.89%
309,053 $1.85 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $142,366 - $168,038
21,217 Added 5.82%
385,782 $2.73 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $1.33 Million - $1.68 Million
191,180 Added 110.26%
364,565 $2.57 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $67,624 - $100,841
8,517 Added 5.17%
173,385 $1.45 Million
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $14,857 - $20,093
1,415 Added 0.87%
164,868 $1.89 Million
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $253,392 - $347,798
-23,484 Reduced 12.56%
163,453 $2.06 Million
Q2 2022

Aug 22, 2022

BUY
$7.89 - $17.88 $27,536 - $62,401
3,490 Added 1.9%
186,937 $1.98 Million
Q1 2022

May 16, 2022

BUY
$11.56 - $19.76 $299,230 - $511,487
25,885 Added 16.43%
183,447 $2.98 Million
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $167 - $231
15 Added 0.01%
157,562 $2.18 Million
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $1.58 Million - $1.97 Million
111,484 Added 242.03%
157,547 $2.26 Million
Q2 2021

Aug 12, 2021

SELL
$9.5 - $17.24 $33,335 - $60,495
-3,509 Reduced 7.08%
46,063 $728,000
Q1 2021

May 17, 2021

SELL
$7.37 - $13.61 $14,821 - $27,369
-2,011 Reduced 3.9%
49,572 $504,000
Q4 2020

Feb 12, 2021

BUY
$3.37 - $8.61 $49,586 - $126,687
14,714 Added 39.91%
51,583 $384,000
Q3 2020

Nov 13, 2020

SELL
$3.43 - $5.53 $13,898 - $22,407
-4,052 Reduced 9.9%
36,869 $126,000
Q2 2020

Aug 14, 2020

SELL
$1.9 - $5.61 $771 - $2,277
-406 Reduced 0.98%
40,921 $195,000
Q1 2020

May 14, 2020

BUY
$1.6 - $4.11 $4,163 - $10,694
2,602 Added 6.72%
41,327 $83,000
Q4 2019

Feb 13, 2020

BUY
$1.59 - $3.45 $16,127 - $34,993
10,143 Added 35.49%
38,725 $134,000
Q3 2019

Nov 13, 2019

BUY
$2.5 - $3.73 $17,642 - $26,322
7,057 Added 32.79%
28,582 $82,000
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $6,431 - $20,221
2,210 Added 11.44%
21,525 $82,000
Q4 2018

Feb 15, 2019

BUY
$6.51 - $9.6 $15,969 - $23,548
2,453 Added 14.55%
19,315 $156,000
Q3 2018

Nov 20, 2018

BUY
$5.52 - $7.99 $6,248 - $9,044
1,132 Added 7.2%
16,862 $129,000
Q2 2018

Aug 10, 2018

SELL
$4.6 - $6.52 $9,747 - $13,815
-2,119 Reduced 11.87%
15,730 $90,000
Q1 2018

May 17, 2018

SELL
$4.35 - $5.82 $27,909 - $37,341
-6,416 Reduced 26.44%
17,849 $85,000
Q4 2017

Feb 13, 2018

BUY
$4.16 - $5.33 $100,942 - $129,332
24,265
24,265 $120,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.42B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.